Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14365561 | 1.00 | CYP1A2 (0.50) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL14312045 | 1.00 | CYP1A2 (0.50) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| Hydrochloric Acid SCHEMBL28730328 | 0.98 | CYP1A2 (0.48) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| Hydrochloric Acid SCHEMBL27570937 | 0.98 | CYP1A2 (0.48) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| Hydrochloric Acid SCHEMBL6895435 | 0.98 | CYP1A2 (0.48) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| Hydrochloric Acid SCHEMBL29646459 | 0.98 | CYP1A2 (0.48) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL19640023 | 0.92 | HTT (0.49) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL19640106 | 0.92 | HTT (0.49) | CYP1A2TDP1HSD17B10HTR1ANPC1 | |
| SCHEMBL22361465 | 0.84 | CHRNB2 (0.42) | CYP3A4HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL19982036 | 0.83 | CYP1A2 (0.46) | CYP1A2TDP1HSD17B10HTR1ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223759-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Broadenbio Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022095904-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京伯汇生物技术有限公司 | 2022-05-12 | — | — | WO | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| US-20180009787-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-11 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-9802919-B1 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-10-31 | — | — | US | disclosed |
| EP-2536285-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | High Point Pharmaceuticals, LLC (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103018-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2010077663-A2 | SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | CYP1A2 623/4885TDP1 700/4885HSD17B10 3805/4885 |
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | CYP1A2 1100/4885TDP1 2164/4885HSD17B10 321/4885 |
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | CYP1A2 1838/4885TDP1 1345/4885HSD17B10 298/4885 |
| US-20180009787-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | CYP1A2 2698/4885TDP1 2881/4885HSD17B10 418/4885 |
| US-20100261706-A1 | SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF | TNNI3, TNNT2, ALDH1A2 | CYP1A2 909/4885TDP1 217/4885HSD17B10 2747/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | CYP1A2 1851/4885TDP1 671/4885HSD17B10 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.